Stephanie M.
Morris
,
MD
3901 Greenspring Ave.
Baltimore, MD 21211
United States
About
Dr. Stephanie Morris is a pediatric neurologist who specializes in caring for children with complex developmental, behavioral, and neurologic conditions, including autism spectrum disorder, developmental delay, attention-deficit/hyperactivity disorder (ADHD), and genetic conditions such as neurofibromatosis. She holds joint appointments at Kennedy Krieger Institute and the Johns Hopkins University School of Medicine.
Dr. Morris serves as medical director of the Center for Autism Services, Science and Innovation (CASSI™) at Kennedy Krieger Institute, where she leads a multidisciplinary team focused on providing comprehensive, individualized care for children with neurodevelopmental differences. She works closely with families to understand each child’s strengths and challenges to develop thoughtful, practical treatment plans.
Dr. Morris also serves as director of the Pediatric Neurofibromatosis (NF) Program at Kennedy Krieger Institute, and assistant director of Pediatric Care at the Johns Hopkins Comprehensive Neurofibromatosis (NF) Center. In these roles, she provides longitudinal care for children with neurofibromatosis and related conditions. Her approach emphasizes early identification of developmental challenges, coordination across medical specialists, and long-term support as children grow and develop.
Before joining Kennedy Krieger Institute, Dr. Morris was on faculty at Washington University in St. Louis, where she helped lead multidisciplinary programs for children with neurodevelopmental and neurogenetic conditions, including neurofibromatosis and Fragile X syndrome.
Education
Dr. Morris earned her medical degree from the University of Arizona College of Medicine and completed residency training in child neurology at Washington University in St. Louis, where she served as chief resident.
Research Summary:
Dr. Morris’ research focuses on understanding neurodevelopmental outcomes in children with neurogenetic conditions, particularly neurofibromatosis type 1 (NF1) and Fragile X syndrome. She has served as site principal investigator for numerous Fragile X clinical trials both at Washington University and Kennedy Krieger Institute (NCT02920892, NCT05367960, NCT05163808, NCT05358886, NCT07209462), as well as clinical trials for children with autism spectrum disorder (NCT06866275).
She is actively involved in the development of novel screening tools to identify neurobehavioral outcomes in children with NF1 and has helped co-lead and organize the annual Cognition and Behavior in NF1 (CABIN) conference. Through this work, Dr. Morris has emerged as a national leader in the study of cognition and behavior in NF1.